Accent TherapeuticsListed
No domain yetbiotech_life_sciences
Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to t…
Portfolio
A closer look at the companies associated with this firm. Verified team members can update the portfolio after signing in.
This is the portfolio currently shown on the public firm page.
Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to t…
Biotechnology company developing precision therapeutics for genetically defined rare and common diseases. It combines genetics, drug discovery, and data science to identify shared…
Biotechnology company developing novel oral small-molecule therapies for underserved rare diseases, with a focus on targeted, patient-friendly treatments where few options exist.
Ambagon Therapeutics is developing a new class of medicines that can modulate previously undruggable targets and influence currently accessible ones in new ways, focusing on 14-3-…
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing best-in-class combination therapies for cancer. The company utilizes a deep understanding of…
Aura Biosciences is a biotech company developing highly tumor-targeted breakthrough therapies for rare cancers, particularly focusing on ocular cancers using a novel viral nanopar…
Cristal Therapeutics is a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient ne…
Clinical-stage oncology biotechnology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. The drug was studied in Phase 1/2 combi…
Frontier Medicines is focused on delivering breakthrough medicines by utilizing a unique scientific approach that combines chemoproteomics and artificial intelligence for covalent…
Private, clinical-stage biotechnology company developing RNA-based cancer immunotherapies, with a focus on dermato-oncology. Its lead candidate BO-112 is an intratumoral RNA-based…
Biotechnology company developing precision immunotherapies for autoimmune diseases. Its lead antibody program, HSB-101, selectively depletes TRBV9-positive T cells for axial spond…
Hummingbird Bioscience is a precision biotherapeutics company developing novel therapies for cancer treatment using advanced technologies and platforms.
Biotechnology company developing precision covalent medicines using a proprietary chemoproteomics discovery platform. The platform maps histidine-, tyrosine-, and lysine-based bin…
Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new RNA medicines for systemic and renal diseases. With our STRIKE (Selectively Targe…
Mahzi Therapeutics is a clinical-stage biotechnology company developing precision therapies for neurogenetic disorders in partnership with patient organizations and academic colla…
Montis Biosciences is a preclinical-stage biopharmaceutical company advancing innovative therapeutics to treat inflammation-driven autoimmune disorders and neurodegenerative disea…
Muna Therapeutics is a privately held biopharmaceutical company focused on discovering and developing therapies that slow or stop neurodegenerative diseases including Alzheimer’s,…
OCTIMET Oncology is a clinical-stage oncology biotechnology company developing highly selective MET kinase inhibitors licensed from Janssen Pharmaceutica. Its development strategy…
Protego Biopharma is a clinical-stage biotechnology company dedicated to pioneering first-in-class small molecule therapeutics that reprogram protein folding to address systemic a…
QurAlis is a biotech company developing precision medicines for ALS and other neurological diseases.
Clinical-stage precision-medicine biotechnology company developing small-molecule therapies for rare genetic diseases and related expansion indications. Its lead TRPV4 inhibitor,…
Tusk Therapeutics appears to be a biotechnology company developing antibody-based immunotherapies for cancer. The search results do not directly describe Tusk; the Mestag Therapeu…
Unnatural Products is a California-based biotech company focused on innovative medicine development, aiming to tackle challenging medical targets.
Details are not available yet. The company remains listed.
Volastra is an NYC-based clinical stage biotechnology company dedicated to the discovery and development of oncology therapeutics targeting chromosomal instability, or CIN, a key…
Vaderis Therapeutics is a Swiss biopharmaceutical company focused on rare vascular diseases, developing VAD044 for Hereditary Hemorrhagic Telangiectasia (HHT).